Han SC, 章青, 陆嘉德. 大肿块ⅠB、ⅡA期及局部晚期宫颈癌的治疗[J]. 中国癌症杂志, 2006, 16(11): 890-895.
[2]
Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer: a systematic review[J]. Gynecol Oncol, 2009, 114 (3): 528-535.
Tabata T, Takeshima N, Nishida H, et al. A randomized study of primary bleomycin, vincristine, mitomycin and cisplatin (BOMP) chemotherapy followed by radiotherapy versus radiotherapy alone in stage IIIB and IVA squamous cell carcinoma of the cervix[J]. Anticancer Res, 2003, 23(3C): 2885-2890.
[5]
Tierney J. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review andmeta-analysis of individual patient data from 21 randomized trials[J]. Eur J Cancer, 2003, 39 (17): 2470-2486.
[6]
Bader HA, Winter R, Moinfar F, et al. Is intraoperative frozen section analysis of pelvic lymph nodes accurate after neoadjuvant chemotherapy in patients with cervical cancer[J]. Gynecol Oncol, 2006, 103(1): 106-112.
[7]
Chun M. Time for global efforts with clinical trials for advanced cervical cancer patients[J]. J Gynecol Oncol, 2009, 20(4): 201-202.
[8]
Kumar JV, Doval DC, Rao R, et al. A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery[J]. Int J Gynecol Cancer, 2009, 19(3): 417- 422.
Term rungruanglert W, Tresukosol D, Vasuratna A, et al. Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2[J]. Gynecol Oncol, 2005, 97(2): 576-581.
[11]
Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study[J]. J Clin Oncol, 2002, 20(1): 179-188.
[12]
Cho YH, Kim DY, Kim JH, et al. Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage ⅠB2-ⅡA bulky cervical cancer[J]. J Gynecol Oncol, 2009, 20 (1): 22-27.
[13]
Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J]. Cochrane DatabaseSyst Rev, 2010, 20(1): CD007406.
[14]
Benedet JL, Pecorelli S, Hacker NF, et al. Staging classifications and clinical practice guidelines of gynaecologic cancer[M/OL]. http://www.figo.org/files/figo-corp/docs/staging_booklet.pdf
Saito T, Takehara M, Lee R, et al. Neoadjuvant chemotherapy with cisplatin, aclacinomycin A, and mitomycin C for cervical adenocarcinoma: a preliminary study[J]. Int J Gynecol Cancer, 2004, 14(3): 483-490.
[19]
Loizzi V, Cormio G, Vicino M, et al. Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer[J]. Gynecol Obstet Invest, 2008, 65(2): 96-103.
[20]
Hwang YY, Moon H, Cho SH, et al. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy[J]. Gynecol Oncol, 2001, 82(1): 88-93.
[21]
Park DC, Suh MJ, Yeo SG. Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results[J]. Int J Gynecol Cancer, 2009, 19(5): 943-947.
Bae JH, Lee SJ, Lee A. Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer[J]. Gynecol Oncol, 2008, 111(3): 444-448.
[24]
Chen H, Liang C, Zhang L, et al. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage ⅠB2 to ⅡB) cervical cancer: randomized study[J]. Gynecol Oncol, 2008, 110(3): 308-315.
Ki KD, Song DH, Tong SY, et al. Neoadjuvant chemotherapy in bulky stage ⅠB-ⅡA cervical cancer: results of a quick course with vincristine, bleomycin, and cisplatin[J]. Int J Gynecol Cancer, 2009, 19(1): 50-53.
Kuzuya K. Chemoradiotherapy for uterine cancer: current status and perspectives[J]. Int J Clin Oncol, 2004, 9(6): 458-470.
[29]
Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage ⅠB cervical carcinoma[J]. N Engl J Med, 1999, 340(15): 1154-1161.
[30]
Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer[J]. N Engl J Med, 1999, 340(15): 1137-1143.
[31]
Peters WA III, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix[J]. J Clin Oncol, 2000, 18(8): 1606-1613.
[32]
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999, 340(15): 1144-1153.
[33]
Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study[J]. J Clin Oncol, 1999, 17(5): 1339-1348.
Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01[J]. J Clin Oncol, 2004, 22(5): 872-880.
Zhao EF, Bao L, Li C, et al. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years[J]. J First Mil Med Univ, 2005, 25(6): 605-609.
[38]
Frei E. Clinical cancer research: an embattled species[J]. Cancer, 1982, 50(10): 1979-1992.
[39]
Ryu HS, Kang SB, Kim KT, et al. Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005)[J]. Int J Gynecol Cancer, 2007, 17(1): 132-136.
Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome C by the mitochondrial channel VDAC[J]. Nature, 1999, 399(6735): 483-487.
Robati M, Holtz D, Dunton CJ. A review of topotecan in combination chemotherapy for advanced cervical cancer[J]. Ther Clin Risk Manag, 2008, 4(1): 213-218.
[44]
Souhami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage ⅢB carcinoma of the cervix[J]. J Clin Oncol, 1991, 9(6): 970-977.
[45]
Duenas-Gonzalez A, Lopez-graniel C, Gonzalez-Enciso A, et al. Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase Ⅱ studies[J]. Ann Oncol, 2002, 13(8): 1212-1219.
[46]
Gonzalez-Martin A, Gonzalez-Cortijo L, Carballo N, et al. The current role of neoadjuvant chemotherapy in the management of cervical carcinoma[J]. Gynecol Oncol, 2008, 110(3 Suppl 2): S36-S40.
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium[J]. Int J Gynaecol Obstet, 2009, 105(2): 103-104.
[49]
Timotheadou E, Gore ME. Neoadjuvant chemotherapy for locally advanced cervical cancer[J]. Eur J Cancer, 2003, 39(17): 2419-2421.
[50]
Tiersten AD, Selleck MJ, Hershman DL, et al. Phase Ⅱ study of topotecan and paclitaxel for persistent, or metastatic cervical cancer[J]. Gynecol Oncol, 2004, 92(2): 635-638.
[51]
Eddy G, Bundy B, CreasmanW, et al. Treatment of (bulky)stage Ⅰb cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical surgery and pelvic/para-aortic lymphadenectomy: a phase Ⅲ trial of the gynecologic oncology group[J]. Gynecol Oncol, 2007, 106(2): 362-369.
